<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1096155" disease_type="Disease or Syndrome" abbrv="">Macrophage activation syndrome</z:e> (MAS), a recognized complication of systemic <z:hpo ids='HP_0005681'>juvenile rheumatoid arthritis</z:hpo> (sJRA), has been associated with significant morbidity and mortality </plain></SENT>
<SENT sid="1" pm="."><plain>Dysregulation of macrophage-lymphocyte interactions leading to uncontrolled proliferation of highly activated macrophages and massive release of proinflammatory cytokines including <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-alpha (TNF-alpha) appears to be central to the pathogenesis of this syndrome </plain></SENT>
<SENT sid="2" pm="."><plain>Until now the mainstay of therapy has been <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> and <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>We describe a patient with MAS and sJRA successfully treated with the anti-TNF agent etanercept </plain></SENT>
<SENT sid="4" pm="."><plain>The outcome in this patient suggests etanercept might be an effective therapeutic agent in MAS </plain></SENT>
</text></document>